Genetic Data From 23andMe Ends Up With This Company In $256 Million Deal
Written by Emily J. Thompson, Senior Investment Analyst
Updated: May 19 2025
0mins
Should l Buy REGN?
Source: Benzinga
Regeneron Acquires 23andMe Assets: Regeneron Pharmaceuticals has won a $256 million bid for key assets of 23andMe, including its Personal Genome Service and Biobank, to enhance its genetics-based drug discovery efforts while ensuring consumer services remain uninterrupted.
Commitment to Privacy and Ethical Data Use: Regeneron has pledged to uphold 23andMe's privacy policies and will have a Customer Privacy Ombudsman oversee data use, emphasizing ethical practices in leveraging genomic research for health advancements.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy REGN?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on REGN
Wall Street analysts forecast REGN stock price to rise
22 Analyst Rating
16 Buy
6 Hold
0 Sell
Moderate Buy
Current: 721.050
Low
637.00
Averages
808.50
High
1057
Current: 721.050
Low
637.00
Averages
808.50
High
1057
About REGN
Regeneron Pharmaceuticals, Inc. is a fully integrated biotechnology company. The Company invents, develops, manufactures, and commercializes medicines for people with serious diseases. Its products and product candidates in development are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, neurological diseases, hematologic conditions, infectious diseases, and rare diseases. The Company is accelerating drug development using its proprietary technologies, such as VelociSuite, which produces optimized fully human antibodies and new classes of bispecific antibodies. VelociSuite consists of VelocImmune, VelociGene, VelociMouse, VelociMab, Veloci-Bi, VelociT, VelociHum, and other related technologies. Its marketed products include EYLEA (aflibercept); Dupixent (dupilumab); Libtayo (cemiplimab); Ordspono (odronextamab); Kevzara (sarilumab); Itepekimab; Lynozyfic, and others.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Regeneron Secures Accelerated Approval for Gene Therapy Otarmeni
- FDA Accelerated Approval: On April 23, Regeneron announced that the FDA granted accelerated approval for its gene therapy Otarmeni, making it the first gene therapy for OTOF-related hearing loss, marking a significant breakthrough for the company in the rare disease sector.
- Clinical Trial Results: In a clinical trial involving 20 patients, 80% showed hearing improvement, and 42% achieved normal hearing after 48 weeks, which not only enhances patient quality of life but also boosts Regeneron's reputation in the gene therapy market.
- Market Strategy Analysis: Although Otarmeni will be offered for free to U.S. patients, this decision reflects Regeneron's strategic consideration of a small market, with only 20 to 50 newborn diagnoses annually, indicating a thoughtful approach to brand image and market testing.
- Future Development Potential: By acquiring Otarmeni through the purchase of Decibel Therapeutics, Regeneron may use this therapy as a pilot for other gene therapies targeting larger patient populations, further expanding its market opportunities in hearing loss treatment.
See More
Analysis of Cash-Strong Companies
- Quest Resource Performance Decline: Quest Resource (NASDAQ:QRHC) has a free cash flow margin of 3.7%, yet its sales have declined by an average of 6.9% annually over the past two years, indicating a lack of competitiveness that limits its growth potential.
- High Debt Risk: The company has a free cash flow margin of -0.3% over the last five years, and a net debt-to-EBITDA ratio of 7x increases the risk of forced asset sales or dilutive financing, further constraining its ability to self-fund growth.
- Regeneron Growth Challenges: Regeneron (NASDAQ:REGN) boasts a free cash flow margin of 27.6%, but its average annual revenue growth is only 6.7%, reflecting the double-edged sword effect of scale that limits its growth potential compared to smaller competitors.
- UnitedHealth Competitive Edge: UnitedHealth (NYSE:UNH) has a free cash flow margin of 4.4% and has achieved an 11.3% annual revenue growth over the past five years, demonstrating its strong competitive position and profitability in the health insurance market.
See More
Regeneron Reports Strong Q1 Earnings Amid Eylea Sales Decline
- Strong Earnings: Regeneron reported Q1 revenue of $3.6 billion, a 19% year-over-year increase that surpassed analysts' expectations of $3.48 billion, while EPS was $6.75, down 7% year-over-year, but adjusted EPS rose 15% to $9.47, indicating resilience in profitability.
- Eylea Sales Decline: Total sales of Eylea fell 10% to $941 million, yet Eylea HD sales surged 52% to $468 million, suggesting that the company's strategic adjustments to counter competition may be effective.
- New Therapy Approval: The FDA granted approval for Otarmeni as the first gene therapy, which will be offered for free in the U.S., but Regeneron plans to charge traditional prices abroad, a strategy that could help safeguard the profitability of its overall portfolio.
- Ongoing R&D Investment: Regeneron expects to spend $6 billion on R&D in 2026, and despite the pressure from declining Eylea sales, the company maintains a gross margin of 76%, demonstrating its competitiveness and conservative capital management in the high-growth biotech sector.
See More
Regeneron Pharmaceuticals Reports Strong Q1 Earnings and $3B Share Buyback Plan
- Strong Earnings Report: Regeneron Pharmaceuticals reported impressive Q1 earnings, with specific financial metrics undisclosed, yet analysts generally believe this will positively impact the company's future growth trajectory.
- Share Buyback Announcement: The company also announced a $3 billion share buyback, a move that not only reflects management's confidence in the company's future prospects but could also enhance earnings per share, thereby attracting more investors.
- Mixed Analyst Views: Despite the strong earnings report, analysts have mixed opinions on Regeneron's stock, with some expressing optimism about its future growth while others voice concerns regarding market competition and the product pipeline.
- Market Reaction Monitoring: Investors should closely monitor market reactions to the earnings report and buyback plan, as differing analyst opinions may lead to stock price volatility, impacting investor decision-making.
See More
Regeneron Reports Strong Q1 2026 Earnings with Key Growth Drivers
- Significant Revenue Growth: In Q1 2026, Regeneron reported total revenues of $3.6 billion, reflecting a 19% year-over-year increase, indicating strong market performance in key products, particularly Dupixent and EYLEA HD.
- Strong Dupixent Sales: Global net sales of Dupixent increased by 31% to $4.9 billion in the quarter, showcasing sustained demand and the company's competitive edge in the immunology sector.
- New Product Approval: Regeneron received FDA approval for Otarmeni for genetic hearing loss and committed to offering the product for free, demonstrating the company's dedication to innovative drug development and patient care.
- Share Buyback Program: The board authorized a $3 billion share repurchase program, reflecting confidence in the company's financial position while also creating additional value for shareholders.
See More
Regeneron and Biogen See High Options Trading Volume
- Regeneron Options Volume: Regeneron Pharmaceuticals, Inc. recorded options trading volume of 3,177 contracts, representing approximately 317,700 shares, which is about 47.9% of its average daily trading volume of 663,385 shares over the past month, indicating strong market interest in its future performance.
- High Call Option Activity: Within Regeneron, the $795 strike call option is particularly active, with 1,091 contracts traded today, representing approximately 109,100 shares, reflecting investor expectations for a price increase.
- Biogen Options Trading: Biogen Inc. saw options trading volume of 5,898 contracts, equating to approximately 589,800 shares, or about 43.3% of its average daily trading volume of 1.4 million shares over the past month, demonstrating significant market interest in its stock.
- Active Put Option Trading: For Biogen, the $170 strike put option has seen trading of 1,509 contracts, representing approximately 150,900 shares, indicating investor concerns regarding potential price declines.
See More
Regeneron Secures Accelerated Approval for Gene Therapy Otarmeni
- FDA Accelerated Approval: On April 23, Regeneron announced that the FDA granted accelerated approval for its gene therapy Otarmeni, making it the first gene therapy for OTOF-related hearing loss, marking a significant breakthrough for the company in the rare disease sector.
- Clinical Trial Results: In a clinical trial involving 20 patients, 80% showed hearing improvement, and 42% achieved normal hearing after 48 weeks, which not only enhances patient quality of life but also boosts Regeneron's reputation in the gene therapy market.
- Market Strategy Analysis: Although Otarmeni will be offered for free to U.S. patients, this decision reflects Regeneron's strategic consideration of a small market, with only 20 to 50 newborn diagnoses annually, indicating a thoughtful approach to brand image and market testing.
- Future Development Potential: By acquiring Otarmeni through the purchase of Decibel Therapeutics, Regeneron may use this therapy as a pilot for other gene therapies targeting larger patient populations, further expanding its market opportunities in hearing loss treatment.
See More
Analysis of Cash-Strong Companies
- Quest Resource Performance Decline: Quest Resource (NASDAQ:QRHC) has a free cash flow margin of 3.7%, yet its sales have declined by an average of 6.9% annually over the past two years, indicating a lack of competitiveness that limits its growth potential.
- High Debt Risk: The company has a free cash flow margin of -0.3% over the last five years, and a net debt-to-EBITDA ratio of 7x increases the risk of forced asset sales or dilutive financing, further constraining its ability to self-fund growth.
- Regeneron Growth Challenges: Regeneron (NASDAQ:REGN) boasts a free cash flow margin of 27.6%, but its average annual revenue growth is only 6.7%, reflecting the double-edged sword effect of scale that limits its growth potential compared to smaller competitors.
- UnitedHealth Competitive Edge: UnitedHealth (NYSE:UNH) has a free cash flow margin of 4.4% and has achieved an 11.3% annual revenue growth over the past five years, demonstrating its strong competitive position and profitability in the health insurance market.
See More
Regeneron Reports Strong Q1 Earnings Amid Eylea Sales Decline
- Strong Earnings: Regeneron reported Q1 revenue of $3.6 billion, a 19% year-over-year increase that surpassed analysts' expectations of $3.48 billion, while EPS was $6.75, down 7% year-over-year, but adjusted EPS rose 15% to $9.47, indicating resilience in profitability.
- Eylea Sales Decline: Total sales of Eylea fell 10% to $941 million, yet Eylea HD sales surged 52% to $468 million, suggesting that the company's strategic adjustments to counter competition may be effective.
- New Therapy Approval: The FDA granted approval for Otarmeni as the first gene therapy, which will be offered for free in the U.S., but Regeneron plans to charge traditional prices abroad, a strategy that could help safeguard the profitability of its overall portfolio.
- Ongoing R&D Investment: Regeneron expects to spend $6 billion on R&D in 2026, and despite the pressure from declining Eylea sales, the company maintains a gross margin of 76%, demonstrating its competitiveness and conservative capital management in the high-growth biotech sector.
See More
Regeneron Pharmaceuticals Reports Strong Q1 Earnings and $3B Share Buyback Plan
- Strong Earnings Report: Regeneron Pharmaceuticals reported impressive Q1 earnings, with specific financial metrics undisclosed, yet analysts generally believe this will positively impact the company's future growth trajectory.
- Share Buyback Announcement: The company also announced a $3 billion share buyback, a move that not only reflects management's confidence in the company's future prospects but could also enhance earnings per share, thereby attracting more investors.
- Mixed Analyst Views: Despite the strong earnings report, analysts have mixed opinions on Regeneron's stock, with some expressing optimism about its future growth while others voice concerns regarding market competition and the product pipeline.
- Market Reaction Monitoring: Investors should closely monitor market reactions to the earnings report and buyback plan, as differing analyst opinions may lead to stock price volatility, impacting investor decision-making.
See More
Regeneron Reports Strong Q1 2026 Earnings with Key Growth Drivers
- Significant Revenue Growth: In Q1 2026, Regeneron reported total revenues of $3.6 billion, reflecting a 19% year-over-year increase, indicating strong market performance in key products, particularly Dupixent and EYLEA HD.
- Strong Dupixent Sales: Global net sales of Dupixent increased by 31% to $4.9 billion in the quarter, showcasing sustained demand and the company's competitive edge in the immunology sector.
- New Product Approval: Regeneron received FDA approval for Otarmeni for genetic hearing loss and committed to offering the product for free, demonstrating the company's dedication to innovative drug development and patient care.
- Share Buyback Program: The board authorized a $3 billion share repurchase program, reflecting confidence in the company's financial position while also creating additional value for shareholders.
See More
Regeneron and Biogen See High Options Trading Volume
- Regeneron Options Volume: Regeneron Pharmaceuticals, Inc. recorded options trading volume of 3,177 contracts, representing approximately 317,700 shares, which is about 47.9% of its average daily trading volume of 663,385 shares over the past month, indicating strong market interest in its future performance.
- High Call Option Activity: Within Regeneron, the $795 strike call option is particularly active, with 1,091 contracts traded today, representing approximately 109,100 shares, reflecting investor expectations for a price increase.
- Biogen Options Trading: Biogen Inc. saw options trading volume of 5,898 contracts, equating to approximately 589,800 shares, or about 43.3% of its average daily trading volume of 1.4 million shares over the past month, demonstrating significant market interest in its stock.
- Active Put Option Trading: For Biogen, the $170 strike put option has seen trading of 1,509 contracts, representing approximately 150,900 shares, indicating investor concerns regarding potential price declines.
See More
